E11/Podoplanin Protein Stabilization Through Inhibition of the Proteasome Promotes Osteocyte Differentiation in Murine in Vitro Models

Journal of Cellular Physiology

Volumn 231, Issue 6, 2016, Pages 1392-1404

  Staines, Katherine A ^a   Prideaux, Matt ^b   Allen, Steve ^c   Buttle, David J ^d   Pitsillides, Andrew A ^c   Farquharson, Colin ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c ROYAL VETERINARY COLLEGE   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CALPAIN 1; CALPAIN 2; GLYCOPROTEIN E; LACTACYSTIN; MEMBRANE PROTEIN; MESSENGER RNA; PODOPLANIN; PROTEASOME; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SCLEROSTIN; TRANSMEMBRANE GLYCOPROTEIN E11; UNCLASSIFIED DRUG; WITHAFERIN A; CALPAIN; CYSTEINE PROTEINASE INHIBITOR; GP38 PROTEIN, MOUSE; PROTEASOME INHIBITOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MINERALIZATION; CELL DIFFERENTIATION; CELL SHAPE; CONTROLLED STUDY; DENDRITE; DOSE RESPONSE; EXTRACELLULAR MATRIX; IMMUNOBLOTTING; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; METABOLISM; PHENOTYPE; TIME FACTOR; UBIQUITINATION;

ANIMALS; CALPAIN; CELL DIFFERENTIATION; CELL LINE; CYSTEINE PROTEINASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; MEMBRANE GLYCOPROTEINS; MICE, INBRED C57BL; OSTEOBLASTS; OSTEOCYTES; PHENOTYPE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEIN STABILITY; PROTEOLYSIS; RHO GTP-BINDING PROTEINS; RNA, MESSENGER; TIME FACTORS; TRANSFECTION; UBIQUITINATION;

EID: 84958669487     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25282     Document Type: Article

References (64)

1. Arnsdorf EJ, Tummala P, Kwon RY, Jacobs CR. 2009. Mechanically induced osteogenic differentiation-the role of RhoA, ROCKII, and cytoskeletal dynamics. J Cell Sci 122:546-553.
2. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W. 2001. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Gen 10:537-543.
3. Barragan-Adjemian C, Nicolella D, Dusevich V, Dallas MR, Eick JD, Bonewald LF. 2006. Mechanism by which MLO-A5 late osteoblasts/early osteocytes mineralize in culture: Similarities with mineralization of lamellar bone. Calcif Tissue Int 79:340-353.
4. Bonewald LF. 2002. Osteocytes: A proposed multifunctional bone cell. J Musculoskelet Neuronal Interact 2:239-241.
5. Bonewald LF. 2007. Osteocyte messages from a bony tomb. Cell Metab 5:410-411.
6. Bonewald LF. 2012. The amazing osteocyte. J Bone Miner Res 26:229-238.
7. Butkinaree C, Park K, Hart GW. 2010. O-linked beta-N-acetylglucosamine (O-GlcNAc): Extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress. Biochim Biophys Acta 1800:96-106.
8. Butler JE, Moore MB, Presnell SR, Chan HW, Chalupny NJ, Lutz CT. 2009. Proteasome regulation of ULBP1 transcription. J Immunol 182:6600-6609.
9. Cao YX, Ramirez MI, Williams MC. 2003. Enhanced binding of Sp1/Sp3 transcription factors mediates the hyperoxia-induced increased expression of the lung type I cell gene T1alpha. J Cell Biochem 89:887-901.
10. Dallas SL, Prideaux M, Bonewald LF. 2013. The osteocyte: An endocrine cell...and more. Endocr Rev 34:658-690.
11. Duffy P, Schmandke A, Schmandke A, Sigworth J, Narumiya S, Cafferty WB, Strittmatter SM. 2009. Rho-associated kinase II (ROCKII) limits axonal growth after trauma within the adult mouse spinal cord. J Neurosci 29:15266-15276.
12. Fu J, Gerhardt H, McDaniel JM, Xia B, Liu X, Ivanciu L, Ny A, Hermans K, Silasi-Mansat R, McGee S, Nye E, Ju T, Ramirez MI, Carmeliet P, Cummings RD, Lupu F, Xia L. 2008. Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in mice. J Clin Invest 118:3725-3737.
13. Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G, Harris SE, Gallwitz W, Kim KB, Hu S, Crews CM, Mundy GR. 2003. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 111:1771-1782.
14. Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, Javed A, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 2005. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 280:33132-33140.
15. Giguere CJ, Schnellmann RG. 2008. Limitations of SLLVY-AMC in calpain and proteasome measurements. Biochem Biophys Res Commun 371:578-581.
16. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M, Mancini C, Martella E, Ferrari L, Tabilio A, Rizzoli V. 2007. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110:334-338.
17. Groger M, Loewe R, Holnthoner W, Embacher R, Pillinger M, Herron GS, Wolff K, Petzelbauer P. 2004. IL-3 induces expression of lymphatic markers Prox-1 and podoplanin in human endothelial cells. J Immunol 173:7161-7169.
18. Harmey D, Stenbeck G, Nobes CD, Lax AJ, Grigoriadis AE. 2004. Regulation of osteoblast differentiation by Pasteurella multocida toxin (PMT): A role for Rho GTPase in bone formation. J Bone Miner Res 19:661-670.
19. Holmbeck K, Bianco P, Pidoux I, Inoue S, Billinghurst RC, Wu W, Chrysovergis K, Yamada S, Birkedal-Hansen H, Poole AR. 2005. The metalloproteinase MT1-MMP is required for normal development and maintenance of osteocyte processes in bone. J Cell Sci 118:147-156.
20. Hong YK, Harvey N, Noh YH, Schacht V, Hirakawa S, Detmar M, Oliver G. 2002. Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev dyn 225:351-357.
21. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T. 2009. Activation of AMP kinase and inhibition of Rho kinase induce the mineralization of osteoblastic MC3T3-E1 cells through endothelial NOS and BMP-2 expression. Am J Physiol Endocrinol Metab 296:E139-E146.
22. Kato Y, Boskey A, Spevak L, Dallas M, Hori M, Bonewald LF. 2001. Establishment of an osteoid preosteocyte-like cell MLO-A5 that spontaneously mineralizes in culture. J Bone Miner Res 16:1622-1633.
23. Khatiwala CB, Kim PD, Peyton SR, Putnam AJ. 2009. ECM compliance regulates osteogenesis by influencing MAPK signaling downstream of RhoA and ROCK. J Bone Miner Res 24:886-898.
24. Laroia G, Cuesta R, Brewer G, Schneider RJ. 1999. Control of mRNA decay by heat shock-ubiquitin-proteasome pathway. Science 284:499-502.
25. Lee SD, Moore CL. 2014. Efficient mRNA polyadenylation requires a ubiquitin-like domain, a zinc knuckle, and a RING finger domain, all contained in the Mpe1 protein. Mol Cell Biol 34:3955-3967.
26. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C. 2009. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578-588.
27. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408.
28. Martin-Villar E, Borda-d'Agua B, Carrasco-Ramirez P, Renart J, Parsons M, Quintanilla M, Jones GE. 2014. Podoplanin mediates ECM degradation by squamous carcinoma cells through control of invadopodia stability. Oncogene 34:4531-4544.
29. Martin-Villar E, Megias D, Castel S, Yurrita MM, Vilaro S, Quintanilla M. 2006. Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci 119:4541-4553.
30. Martin-Villar E, Yurrita MM, Fernandez-Munoz B, Quintanilla M, Renart J. 2009. Regulation of podoplanin/PA2.26 antigen expression in tumour cells. Involvement of calpain-mediated proteolysis. Int J Biochem Cell Biol 41:1421-1429.
31. McBeath R, Pirone DM, Nelson CM, Bhadriraju K, Chen CS. 2004. Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev cell 6:483-495.
32. Meyers VE, Zayzafoon M, Douglas JT, McDonald JM. 2005. RhoA and cytoskeletal disruption mediate reduced osteoblastogenesis and enhanced adipogenesis of human mesenchymal stem cells in modeled microgravity. J Bone Miner Res 20:1858-1866.
33. Nakashima T, Takayanagi H. 2011. New regulation mechanisms of osteoclast differentiation. Ann NY Acad Sci 1240:E13-E18.
34. Nefussi JR, Sautier JM, Nicolas V, Forest N. 1991. How osteoblasts become osteocytes: A decreasing matrix forming process. J Biol buccale 19:75-82.
35. Newton PT, Staines KA, Spevak L, Boskey AL, Teixeira CC, Macrae VE, Canfield AE, Farquharson C. 2012. Chondrogenic ATDC5 cells: An optimised model for rapid and physiological matrix mineralisation. Int J Mol Med 30:1187-1193.
36. Orriss IR, Hajjawi MO, Huesa C, MacRae VE, Arnett TR. 2014. Optimisation of the differing conditions required for bone formation in vitro by primary osteoblasts from mice and rats. Int J Mol Med 34:1201-1208.
37. Palumbo C, Ferretti M, Marotti G. 2004. Osteocyte dendrogenesis in static and dynamic bone formation: An ultrastructural study. Anat Rec A Discov Mol. Cell Evol Biol 278:474-480.
38. Prideaux M, Loveridge N, Pitsillides AA, Farquharson C. 2012. Extracellular matrix mineralization promotes E11/gp38 glycoprotein expression and drives osteocytic differentiation. PLoS ONE 7:e36786.
39. Qiang YW, Heuck CJ, Shaughnessy JD, Jr., Barlogie B, Epstein J. 2012. Proteasome inhibitors and bone disease. Semin Hematol 49:243-248.
40. Qiang YW, Hu B, Chen Y, Zhong Y, Shi B, Barlogie B, Shaughnessy JD, Jr.. 2009. Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 113:4319-4330.
41. Ria R, Reale A, Vacca A. 2014. Novel agents and new therapeutic approaches for treatment of multiple myeloma. World J Methodol 4:73-90.
42. Rockwell CE, Qureshi N. 2010. Differential effects of lactacystin on cytokine production in activated Jurkat cells and murine splenocytes. Cytokine 51:12-17.
43. Roos-Mattjus P, Sistonen L. 2004. The ubiquitin-proteasome pathway. Ann Med 36:285-295.
44. Sanvoranart T, Supokawej A, Kheolamai P, U-Pratya Y, Klincumhom N, Manochantr S, Wattanapanitch M, Issaragrisil S. 2014. Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues. Biochem Biophys Res Commun 447:580-585.
45. Scholl FG, Gamallo C, Vilaro S, Quintanilla M. 1999. Identification of PA2.26 antigen as a novel cell-surface mucin-type glycoprotein that induces plasma membrane extensions and increased motility in keratinocytes. J Cell Sci 112:4601-4613.
46. Shimizu S, Kadowaki M, Yoshioka H, Kambe A, Watanabe T, Kinyamu HK, Eling TE. 2013. Proteasome inhibitor MG132 induces NAG-1/GDF15 expression through the p38 MAPK pathway in glioblastoma cells. Biochem Biophys Res Commun 430:1277-1282.
47. Skaug B, Jiang X, Chen ZJ. 2009. The role of ubiquitin in NF-kappaB regulatory pathways. Ann Rev Biochem 78:769-796.
48. Skerry TM, Bitensky L, Chayen J, Lanyon LE. 1989. Early strain-related changes in enzyme activity in osteocytes following bone loading in vivo. J Bone Miner Res 4:783-788.
49. Sprague L, Wetterwald A, Heinzman U, Atkinson MJ. 1996. Phenotypic changes following over-expression of sense or antisense E11 cDNA in ROS 17/2.8 cells. J Bone Miner Res 11:151-151.
50. Staines KA, Mackenzie NC, Clarkin CE, Zelenchuk L, Rowe PS, MacRae VE, Farquharson C. 2012a. MEPE is a novel regulator of growth plate cartilage mineralization. Bone 51:418-430.
51. Staines KA, Macrae VE, Farquharson C. 2012b. Cartilage development and degeneration: A Wnt Wnt situation. Cell Biochem Funct 30:633-642.
52. Staines KA, Zhu D, Farquharson C, Macrae VE. 2013. Identification of novel regulators of osteoblast matrix mineralization by time series transcriptional profiling. J Bone Mineral Metab. 32:240-251.
53. Suzuki H, Amizuka N, Oda K, Li M, Yoshie H, Ohshima H, Noda M, Maeda T. 2005. Histological evidence of the altered distribution of osteocytes and bone matrix synthesis in klotho-deficient mice. Arch Histol Cytol 68:371-381.
54. Takai Y, Sasaki T, Matozaki T. 2001. Small GTP-binding proteins. Physiol Rev 81:153-208.
55. Terpos E, Sezer O, Croucher P, Dimopoulos MA. 2007. Myeloma bone disease and proteasome inhibition therapies. Blood 110:1098-1104.
56. Uyama M, Sato MM, Kawanami M, Tamura M. 2012. Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib. Genes cells 17:548-558.
57. Wetterwald A, Hoffstetter W, Cecchini MG, Lanske B, Wagner C, Fleisch H, Atkinson M. 1996. Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone 18:125-132.
58. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA. 2003. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267-6276.
59. Woo SM, Rosser J, Dusevich V, Kalajzic I, Bonewald LF. 2011. Cell line IDG-SW3 replicates osteoblast-to-late-osteocyte differentiation in vitro and accelerates bone formation in vivo. J Bone Miner Res 26:2634-2646.
60. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. 2011. Matrix-embedded cells control osteoclast formation. Nat Med 17:1235-1241.
61. Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G. 2005. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Brit J Haematol 131:71-73.
62. Zhang K, Barragan-Adjemian C, Ye L, Kotha S, Dallas M, Lu Y, Zhao S, Harris M, Harris SE, Feng JQ, Bonewald LF. 2006. E11/gp38 selective expression in osteocytes: Regulation by mechanical strain and role in dendrite elongation. Mol Cell Biol 26:4539-4552.
63. Zhao M, Qiao M, Harris SE, Oyajobi BO, Mundy GR, Chen D. 2004. Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo. J Biol Chem 279:12854-12859.
64. Zhao M, Qiao M, Oyajobi BO, Mundy GR, Chen D. 2003. E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation. J Biol Chem 278:27939-27944.